ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Vitiligo-like depigmentation as an accessible readout of antitumour immunity in melanoma immunotherapy.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo-like depigmentation (VLD) arising under immune checkpoint blockade in melanoma is associated with objective tumour response and substantially longer survival. Its prognostic value is not coincidental: depigmentation and tumour regression share a CD8⁺ effector programme directed at melanocyte differentiation antigens and recruited through the IFN-γ-CXCL9/CXCL10-CXCR3 axis, an axis independently required for the efficacy of PD-1 blockade. The depigmenting lesion is therefore an accessible compartment in which the antitumour effector response could, in principle, be measured directly. This opportunity is currently unexploited: VLD is graded by inspection, and its molecular correlates are sought almost exclusively in plasma, where a locally generated chemokine signal is diluted into a whole-body average confounded by tumour burden, concurrent immune-related adverse events and corticosteroid exposure. Paired-matrix data from spontaneous vitiligo show that the same chemokines discriminate active from stable depigmentation several-fold in lesional skin interstitial fluid whilst discriminating poorly in serum from the same patients, a finding not yet tested in the ICI setting. Building on this observation as an explicit hypothesis, we reframe the problem as one of matrix selection, pre-analytical control and analytical validation: we compare skin-proximal and systemic matrices against tumour biopsy and circulating tumour DNA, define the pre-analytical variables that are peculiar to oncology, and outline a translational roadmap by which a validated cutaneous assay could convert a visible prognostic sign into a quantitative, early and repeatable readout of antitumour immunity.
Indexed as
Identifiers
42816734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.